ILUN19174, Mulford, QUILT-2.023, NSCLC, N803
Basic Study Information
Purpose:
This is a phase 3, open-label, 3-cohort, randomized study to compare the safety and
efficacy of N-803 in combination with the current standard of care (experimental arms)
versus standard of care alone (control arms), as first-line treatment for subjects
with stage 3 or 4 advanced or metastatic NSCLC. Treatment will continue for up to
2 years, or until the patient experiences confirmed progressive disease or unacceptable
toxicity, withdraws consent, or if the investigator feels that it is no longer in
the patient's best interest to continue treatment. Patients will be followed for disease
progression, post-therapies, and survival through 24 months after the first dose of
study drug.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Deborah Mulford, MD
Study Contact Information
Study Coordinator: Nichole Ransom
Phone: +1 585-276-8747
Email: nichole_ransom@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search